Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skåne County, Sweden

Katja Troberg, Pernilla Isendahl, Marianne Alanko Blomé, Disa Dahlman, Anders Håkansson, Katja Troberg, Pernilla Isendahl, Marianne Alanko Blomé, Disa Dahlman, Anders Håkansson

Abstract

Background: Continuously high rates of overdose deaths in Sweden led to the decision by the Skåne County to initiate the first regional take-home naloxone program in Sweden. The project aims to study the effect of overdose prevention education and naloxone distribution on overdose mortality in Skåne County. Secondary outcome measures include non-fatal overdoses and overdose-related harm in the general population, as well as cohort-specific effects in study participants regarding overdoses, mortality and retention in naloxone program.

Methods: Implementation of a multi-site train-the-trainer cascade model was launched in June 2018. Twenty four facilities, including opioid substitution treatment units, needle exchange programs and in-patient addiction units were included for the first line of start-up, aspiring to reach a majority of individuals at-risk within the first 6 months. Serving as self-sufficient naloxone hubs, these units provide training, naloxone distribution and study recruitment. During 3 years, questionnaires are obtained from initial training, follow up, every sixth month, and upon refill. Estimated sample size is 2000 subjects. Naloxone distribution rates are reported, by each unit, every 6 months. Medical diagnoses, toxicological raw data and data on mortality and cause of death will be collected from national and regional registers, both for included naloxone recipients and for the general population. Data on vital status and treatment needs will be collected from registers of emergency and prehospital care.

Discussion: Despite a growing body of literature on naloxone distribution, studies on population effect on mortality are scarce. Most previous studies and reports have been uncontrolled, thus not being able to link naloxone distribution to survival, in relation to a comparison period. As Swedish registers present the opportunity to monitor individuals and entire populations over time, conditions for conducting systematic follow-ups in the Swedish population are good, serving the opportunity to study the impact of large scale overdose prevention education and naloxone distribution and thus fill the knowledge gap.

Trial registration: Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications, NCT03570099, registered on 26 June 2018.

Keywords: Needle exchange program; Opioid substitution treatment; Opioids; Substance dependency; Take-home naloxone.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Training model OPEND Skåne Region – flowchart

References

    1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): European Drug Report. Trends and developments. Luxembourg: Publications Office of the European Union. 2019. Accessed 24 Sept 2019.
    1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Drug-induced mortality rates among adults (15–64): selected trends and most recent data. Luxembourg: Publications Office of the European Union. 2019. Accessed 24 Sept 2019.
    1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Sweden: Country Drug Report. Luxembourg: Publications Office of the European Union. 2019. Accessed 24 Sept 2019.
    1. Martins SS, Sampson L, Cerda M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015;105(11):2373. doi: 10.2105/AJPH.2015.302843a.
    1. Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend. 2015;148:209–212. doi: 10.1016/j.drugalcdep.2014.12.009.
    1. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–163. doi: 10.1097/ADM.0000000000000034.
    1. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–253. doi: 10.1080/08897077.2015.1010032.
    1. Buajordet I, Naess AC, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11(1):19–23. doi: 10.1097/00063110-200402000-00004.
    1. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177–1187. doi: 10.1111/add.13326.
    1. World Health Organization (WHO). WHO Guidelines Approved by the Guidelines Review Committee: Community Management of Opioid Overdose. World Health Organization. 2014.
    1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Preventing opioid overdose deaths with take-home naloxone. EMCDDA Insights. Luxembourg: Publications Office of the European Union. 2016. Accessed on 25 Jan 2018.
    1. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1–9. doi: 10.7326/0003-4819-158-1-201301010-00003.
    1. Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value Health. 2018;21(4):407–415. doi: 10.1016/j.jval.2017.07.014.
    1. Banta-Green CJ, Coffin PO, Merrill JO, Sears JM, Dunn C, Floyd AS, Whiteside LK, Yanez ND, Donovan DM. Impacts of an opioid overdose prevention intervention delivered subsequent to acute care. Injury Prevention. 2019;25:191–198. doi: 10.1136/injuryprev-2017-042676.
    1. Madah-Amiri D, Clausen T. The use of public health infrastructure probably the best strategy for national and large-scale naloxone distribution programmes. Addiction. 2016;111(7):1309–1310. doi: 10.1111/add.13400.
    1. Madah-Amiri D, Clausen T, Lobmaier P. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend. 2017;173:17–23. doi: 10.1016/j.drugalcdep.2016.12.013.
    1. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi: 10.1136/bmj.f174.
    1. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(7):616–623. doi: 10.1197/j.aem.2007.04.005.
    1. Stoove MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Review. 2009;28(4):347–352. doi: 10.1111/j.1465-3362.2009.00057.x.
    1. Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51–55. doi: 10.1016/j.drugalcdep.2016.02.024.
    1. Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction. 2003;98(2):185–190. doi: 10.1046/j.1360-0443.2003.00264.x.
    1. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison--a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–165. doi: 10.1056/NEJMsa064115.
    1. Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103(2):251–255. doi: 10.1111/j.1360-0443.2007.02081.x.
    1. Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–1554. doi: 10.1111/j.1360-0443.2010.02990.x.
    1. Ravndal E, Amundsen EJ. Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. Drug Alcohol Depend. 2010;108(1–2):65–69. doi: 10.1016/j.drugalcdep.2009.11.008.
    1. Merrall EL, Bird SM, Hutchinson SJ. A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996–2006. Addiction. 2013;108(2):377–384. doi: 10.1111/j.1360-0443.2012.04066.x.
    1. White SR, Bird SM, Merrall EL, Hutchinson SJ. Drugs-related death soon after hospital-discharge among drug treatment clients in Scotland: record linkage, validation, and investigation of risk-factors. PLoS One. 2015;10(11):e0141073. doi: 10.1371/journal.pone.0141073.
    1. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health. 2003;80(2):261–273. doi: 10.1093/jurban/jtg029.
    1. Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010;106(1):1–6. doi: 10.1016/j.drugalcdep.2009.07.014.
    1. Simonsen KW, Edvardsen HM, Thelander G, Ojanpera I, Thordardottir S, Andersen LV, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int. 2015;248:172–180. doi: 10.1016/j.forsciint.2015.01.003.
    1. Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, et al. A longitudinal study of multiple drug use and overdose among young people who inject drugs. Am J Public Health. 2016;106(5):915–917. doi: 10.2105/AJPH.2016.303084.
    1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Drug-related deaths and mortality in Europe: Update from the EMCDDA expert network. Luxembourg: Publications Office of the European Union. 2019. .
    1. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–227. doi: 10.1111/j.1600-0447.1990.tb03057.x.
    1. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction. 1994;89(2):203–209. doi: 10.1111/j.1360-0443.1994.tb00879.x.
    1. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999;170(3):104–109. doi: 10.5694/j.1326-5377.1999.tb127675.x.
    1. Darke S, Mattick RP, Degenhardt L. The ratio of non-fatal to fatal heroin overdose. Addiction. 2003;98(8):1169–1171. doi: 10.1046/j.1360-0443.2003.00474.x.
    1. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1–2):9–15. doi: 10.1016/j.drugalcdep.2009.05.021.
    1. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51. doi: 10.1111/j.1360-0443.2010.03140.x.
    1. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550.
    1. O'Toole J, Hambly R, Cox AM, O'Shea B, Darker C. Methadone-maintained patients in primary care have higher rates of chronic disease and multimorbidity, and use health services more intensively than matched controls. Eur J Gen Pract. 2014;20(4):275–280. doi: 10.3109/13814788.2014.905912.
    1. Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction. 1996;91(12):1765–1772. doi: 10.1111/j.1360-0443.1996.tb03800.x.
    1. Braback M, Nilsson S, Isendahl P, Troberg K, Bradvik L, Hakansson A. Malmo Treatment Referral and Intervention Study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. Addiction. 2016;111(5):866–873. doi: 10.1111/add.13249.
    1. Brådvik L, Hulenvik P, Frank A, Medvedeo A, Berglund M. Self-reported and observed heroin overdoses in Malmoe. J Subst Use. 2007;12(2):119–126. doi: 10.1080/14659890601178667.
    1. Schachter EN, Basta W. Bronchiectasis following heroin overdose. A report of two cases. Chest. 1973;63(3):363–366. doi: 10.1378/chest.63.3.363.
    1. Sporer KA, Firestone J, Isaacs SM. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med Off J Soc Acad Emerg Med. 1996;3(7):660–667. doi: 10.1111/j.1553-2712.1996.tb03487.x.
    1. Brust JC, Richter RW. Stroke associated with addiction to heroin. J Neurol Neurosurg Psychiatry. 1976;39(2):194–199. doi: 10.1136/jnnp.39.2.194.
    1. Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97(8):963–967. doi: 10.1046/j.1360-0443.2002.00132.x.
    1. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95(5):687–695. doi: 10.1046/j.1360-0443.2000.9556874.x.
    1. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–155. doi: 10.1056/NEJMra1202561.
    1. Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111(9):1607–1613. doi: 10.1111/add.13429.
    1. Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clinical Toxicol. 2017;55(2):81–87. doi: 10.1080/15563650.2016.1253846.
    1. Skulberg Arne Kristian, Åsberg Anders, Khiabani Hasse Zare, Røstad Hilde, Tylleskar Ida, Dale Ola. Pharmacokinetics of a novel, approved, 1.4‐mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. Addiction. 2019;114(5):859–867. doi: 10.1111/add.14552.
    1. United States Department of Health and Human Services. Food and Drug Administration. Centre for Drug Evaluation and Research. 2017. Accessed 5 June 2019.
    1. Barton ED, Ramos J, Colwell C, Benson J, Baily J, Dunn W. Intranasal administration of naloxone by paramedics. Prehospital Emerg Care. 2002;6(1):54–58. doi: 10.1080/10903120290938797.
    1. Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29(3):265–271. doi: 10.1016/j.jemermed.2005.03.007.
    1. Belz D, Lieb J, Rea T, Eisenberg MS. Naloxone use in a tiered-response emergency medical services system. Prehospital Emerg Care. 2006;10(4):468–471. doi: 10.1080/10903120600885134.
    1. Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182(1):24–27. doi: 10.5694/j.1326-5377.2005.tb06550.x.
    1. Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104(12):2067–2074. doi: 10.1111/j.1360-0443.2009.02724.x.
    1. Merlin MA, Saybolt M, Kapitanyan R, Alter SM, Jeges J, Liu J, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. 2010;28(3):296–303. doi: 10.1016/j.ajem.2008.12.009.
    1. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehospital Emerg Care. 2009;13(4):512–515. doi: 10.1080/10903120903144866.
    1. Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? Prehospital Emerg Care. 2012;16(2):289–292. doi: 10.3109/10903127.2011.640763.
    1. Sabzghabaee AM, Eizadi-Mood N, Yaraghi A, Zandifar S. Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial. Archives Med Sci. 2014;10(2):309–314. doi: 10.5114/aoms.2014.42584.
    1. Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addictions. 1994;29(6):819–827. doi: 10.3109/10826089409047912.
    1. Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243–1253. doi: 10.1002/jcph.759.
    1. Mundin G, McDonald R, Smith K, Harris S, Strang J. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction. 2017;112(9):1647–1652. doi: 10.1111/add.13849.
    1. Ryan SA, Dunne RB. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Management. 2018;8(3):231–245. doi: 10.2217/pmt-2017-0060.
    1. McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction. 2018;113(3):484–493. doi: 10.1111/add.14033.
    1. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, et al. Evaluation of a naloxone distribution and administration program in New York City. Substance Use Misuse. 2008;43(7):858–870. doi: 10.1080/10826080701801261.
    1. Strang J, Manning V, Mayet S, Best D, Titherington E, Santana L, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103(10):1648–1657. doi: 10.1111/j.1360-0443.2008.02314.x.
    1. Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. Evaluation of the staying alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy. 2009;20(2):131–136. doi: 10.1016/j.drugpo.2008.03.002.
    1. Gaston RL, Best D, Manning V, Day E. Can we prevent drug related deaths by training opioid users to recognise and manage overdoses? Harm Reduct J. 2009;6:26. doi: 10.1186/1477-7517-6-26.
    1. Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the skid row area of Los Angeles, CA. Int J Drug Policy. 2010;21(3):186–193. doi: 10.1016/j.drugpo.2009.01.003.
    1. Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, et al. How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. Addiction. 2019;114(4):708–718. doi: 10.1111/add.14510.
    1. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–311. doi: 10.1093/jurban/jti053.
    1. Wagner KD, Davidson PJ, Iverson E, Washburn R, Burke E, Kral AH, et al. "I felt like a superhero": the experience of responding to drug overdose among individuals trained in overdose prevention. Int J Drug Policy. 2014;25(1):157–165. doi: 10.1016/j.drugpo.2013.07.003.
    1. Fugelstad A, Thiblin I, Johansson LA, Agren G, Sidorchuk A. Opioid-related deaths and previous care for drug use and pain relief in Sweden. Drug Alcohol Depend. 2019;201:253–259. doi: 10.1016/j.drugalcdep.2019.04.022.
    1. The National Board of Health and Welfare (Socialstyrelsen). Tillgängliggöra naloxon för patienter och personer utanför hälso- och sjukvården. Möjligheter inom ramen för dagens rättsliga regleringar. (Making naloxone available for patients and individuals outside of healthcare. Opportunities within the current legislation). 2017. Accessed 17 June 2019.
    1. Håkansson A, Vedin A, Wallin C, Kral AH. Distribution of naloxone to prevent death from heroin overdose. Study of opioid dependent patients’ attitudes to be part of the antidote program. Läkartidningen. 2013;110:1340–1342.
    1. RedLiv. The Danish Naloxone Program. Accessed 24 October 2017.
    1. The National Board of Health and Welfare (Socialstyrelsen). Socialstyrelsen: Sjuksköterskor får nu möjlighet att förskiva naloxon [Registered nurses can prescribe naloxone]. 2018. Accessed 17 June 2019.
    1. Richert T. Wasted, overdosed, or beyond saving – to act or not to act? Heroin users’ views, assessments, and responses to witnessed overdoses in Malmö, Sweden. Int J Drug Policy. 2015;26:92–99. doi: 10.1016/j.drugpo.2014.07.006.
    1. The National Board of Health and Welfare (Socialstyrelsen). Socialstyrelsen: Stark rekommendation för naloxon i nartionella riktlinjer [The Board: Strong recommendations for naloxone in national guidelines]. 2019. Accessed 17 June 2019.
    1. The Health and Medical Board, Skåne County. Hälso- och sjukvårdsnämnden: Protokoll §§ 22–49, 26 March 2015, Region Skåne. 2015 Accessed 25 Sept 2019.
    1. Jerkeman A, Håkansson A, Rylance R, Wagner P, Alanko Blomé M, Björkman P. Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy. Drug Alcohol Review. 2017;36:424–431. doi: 10.1111/dar.12425.
    1. Åhman A, Jerkeman A, Blomé MA, Björkman P, Håkansson A. Mortality and causes of death among people who inject amphetamine: a long-term follow-up cohort study from a needle exchange program in Sweden. Drug Alcohol Depend. 2018;188:274–280. doi: 10.1016/j.drugalcdep.2018.03.053.
    1. Reepalu A, Blomé MA, Björk J, Widell A, Björkman P. The risk of cancer among persons with a history of injecting drug use in Sweden – a cohort study based on participants in a needle exchange program. Acta Oncol. 2012;51:51–56. doi: 10.3109/0284186X.2011.626445.
    1. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322(7291):895–896. doi: 10.1136/bmj.322.7291.895.
    1. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009;99(5):788–791. doi: 10.2105/AJPH.2008.146647.
    1. Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health. 2010;87(6):931–941. doi: 10.1007/s11524-010-9495-8.
    1. Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment – a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. doi: 10.1016/j.drugalcdep.2017.01.013.
    1. Harm Reduction Coalition (HRC). Overdose Prevention: Best practice. Accessed 24 Oct 2017.
    1. World Health Organization . IDC-10 classifications of mental and Behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
    1. The Naloxone Project, Skåne County (Naloxonprojektet, Region Skåne). Accessed 25 Sept 2019.
    1. Latkin CA, Gicquelais RE, Clyde C, Dayton L, Davey-Rothwell M, German D, et al. Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland. Int J Drug Policy. 2019;68:86–92. doi: 10.1016/j.drugpo.2019.03.012.
    1. Bird SM, McAuley A, Perry S, Hunter C. Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006–10) versus after (2011–13) comparison. Addiction. 2016;111(5):883–891. doi: 10.1111/add.13265.
    1. Parmar MK, Strang J, Choo L, Meade AM, Bird SM. Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. Addiction. 2017;112(3):502–515. doi: 10.1111/add.13668.
    1. McAuley A, Munro A, Bird SM, Hutchinson SJ, Goldberg DJ, Taylor A. Engagement in a National Naloxone Programme among people who inject drugs. Drug Alcohol Depend. 2016;162:236–240. doi: 10.1016/j.drugalcdep.2016.02.031.
    1. Madah-Amiri D, Gjersing L, Clausen T. Naloxone distribution and possession following a large-scale naloxone programme. Addiction. 2019;114(1):92–100. doi: 10.1111/add.14425.
    1. Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, McNeely M, et al. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health. 2013;38(1):133–141. doi: 10.1007/s10900-012-9591-7.
    1. Rowe C, Santos GM, Behar E, Coffin PO. Correlates of overdose risk perception among illicit opioid users. Drug Alcohol Depend. 2016;159:234–239. doi: 10.1016/j.drugalcdep.2015.12.018.
    1. Neale J, Strang J. Naloxone--does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction. 2015;110(10):1644–1652. doi: 10.1111/add.13027.
    1. Latimore AD, Bergstein RS. "caught with a body" yet protected by law? Calling 911 for opioid overdose in the context of the good Samaritan Law. Int J Drug Policy. 2017;50:82–89. doi: 10.1016/j.drugpo.2017.09.010.
    1. McAuley A, Bouttell J, Barnsdale L, Mackay D, Lewsey J, Hunter C, et al. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis. Addiction. 2017;112(2):301–308. doi: 10.1111/add.13602.
    1. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health. 2011;88(6):1020–1030. doi: 10.1007/s11524-011-9600-7.
    1. Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J. 2008;5:2. doi: 10.1186/1477-7517-5-2.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit